MediciNova MNOV Stock
MediciNova Price Chart
MediciNova MNOV Financial and Trading Overview
| MediciNova stock price | 1.2 USD |
| Previous Close | 2.21 USD |
| Open | 2.26 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 2.26 - 2.31 USD |
| 52 Week Range | 1.89 - 2.73 USD |
| Volume | 28.8K USD |
| Avg. Volume | 20.24K USD |
| Market Cap | 113.3M USD |
| Beta (5Y Monthly) | 0.997887 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.23 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.5 USD |
MNOV Valuation Measures
| Enterprise Value | 53.77M USD |
| Trailing P/E | N/A |
| Forward P/E | -7.965517 |
| PEG Ratio (5 yr expected) | -0.38 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.6727009 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -3.796 |
Trading Information
MediciNova Stock Price History
| Beta (5Y Monthly) | 0.997887 |
| 52-Week Change | -9.41% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.73 USD |
| 52 Week Low | 1.89 USD |
| 50-Day Moving Average | 2.18 USD |
| 200-Day Moving Average | 2.22 USD |
MNOV Share Statistics
| Avg. Volume (3 month) | 20.24K USD |
| Avg. Daily Volume (10-Days) | 18.59K USD |
| Shares Outstanding | 49.05M |
| Float | 42.08M |
| Short Ratio | 25.62 |
| % Held by Insiders | 2.98% |
| % Held by Institutions | 23.87% |
| Shares Short | 339.02K |
| Short % of Float | 0.82% |
| Short % of Shares Outstanding | 0.68% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -11.41% |
| Return on Equity (ttm) | -18.36% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -14164497 USD |
| Net Income Avi to Common (ttm) | -13600170 USD |
| Diluted EPS (ttm) | -0.28 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 55.26M USD |
| Total Cash Per Share (mrq) | 1.13 USD |
| Total Debt (mrq) | 631.58K USD |
| Total Debt/Equity (mrq) | 0.93 USD |
| Current Ratio (mrq) | 20.636 |
| Book Value Per Share (mrq) | 1.381 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -12360576 USD |
| Levered Free Cash Flow (ttm) | -7764771 USD |
Profile of MediciNova
| Country | United States |
| State | CA |
| City | La Jolla |
| Address | 4275 Executive Square |
| ZIP | 92037 |
| Phone | 858 373 1500 |
| Website | https://www.medicinova.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 13 |
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
Q&A For MediciNova Stock
What is a current MNOV stock price?
MediciNova MNOV stock price today per share is 1.2 USD.
How to purchase MediciNova stock?
You can buy MNOV shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for MediciNova?
The stock symbol or ticker of MediciNova is MNOV.
Which industry does the MediciNova company belong to?
The MediciNova industry is Biotechnology.
How many shares does MediciNova have in circulation?
The max supply of MediciNova shares is 49.05M.
What is MediciNova Price to Earnings Ratio (PE Ratio)?
MediciNova PE Ratio is now.
What was MediciNova earnings per share over the trailing 12 months (TTM)?
MediciNova EPS is -0.23 USD over the trailing 12 months.
Which sector does the MediciNova company belong to?
The MediciNova sector is Healthcare.
MediciNova MNOV included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
10.08B USD — | 14784.03 USD — | 16292.28 USD — | — - | 10.08B USD — |
| NASDAQ Global Market Composite NQGM | 1638.71 USD — |
-0.55
|
— — | 1547.55 USD — | 1705.12 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19098.57 USD — |
+0.1
|
— — | 18095.83 USD — | 19941.93 USD — | — - | — — |
- {{ link.label }} {{link}}